Pieris Pharmaceuticals (NASDAQ:PIRS) had its target price lifted by HC Wainwright from $9.00 to $12.00 in a research report released on Tuesday morning, MarketBeat reports. They currently have a buy rating on the biotechnology company’s stock.
Several other research analysts also recently weighed in on PIRS. BidaskClub raised shares of Pieris Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, December 27th. ValuEngine downgraded shares of Pieris Pharmaceuticals from a hold rating to a sell rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $10.00.
Shares of Pieris Pharmaceuticals (NASDAQ PIRS) traded up $0.05 during mid-day trading on Tuesday, hitting $7.42. 549,480 shares of the stock were exchanged, compared to its average volume of 480,531. Pieris Pharmaceuticals has a 12-month low of $1.66 and a 12-month high of $7.90. The company has a market cap of $332.37, a P/E ratio of -10.16 and a beta of -76.25.
In related news, major shareholder Orbimed Advisors Llc sold 147,635 shares of the company’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $5.70, for a total value of $841,519.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.05% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in PIRS. Schwab Charles Investment Management Inc. bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $292,000. Rhumbline Advisers bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $184,000. Bank of New York Mellon Corp bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $359,000. Teachers Advisors LLC bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $308,000. Finally, TIAA CREF Investment Management LLC bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $649,000. 50.45% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This report was published by Ticker Report and is owned by of Ticker Report. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3146331/pieris-pharmaceuticals-pirs-price-target-raised-to-12-00.html.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.